{
  "id": "digital-sequence-information",
  "title": "Digital Sequence Information",
  "lang": "en",
  "source_lang": "en",
  "summary": "Digital sequence information is a policy term for digitized genetic sequence data and, in some interpretations, related biological information, central to debates over research access and benefit-sharing.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "DSI",
    "digital sequence information on genetic resources"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/digital-sequence-information/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/digital-sequence-information/",
      "json": "https://aiwiki.page/zh/digital-sequence-information.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Digital sequence information (DSI) is a term used in international policy discussions for biological sequence information represented in digital form, especially the nucleotide sequences of DNA and RNA. Some interpretations also encompass protein sequences and associated biological information. The term has no single, universally agreed definition and is principally associated with negotiations under the Convention on Biological Diversity (CBD). Its importance arises from the ability to study and use genetic information without obtaining or transferring the physical material from which it originated, raising questions about how the benefits of such use should be shared."
    },
    {
      "heading": "Meaning and scope",
      "text": "DSI is a policy expression rather than a precisely bounded category in laboratory science. Researchers more commonly refer to nucleotide sequences, sequence reads, assembled genomes, or other specific data types.\n\nThe least disputed core of DSI consists of digitally recorded nucleotide sequences. These can range from short fragments to a complete genome. Broader proposed interpretations include amino-acid sequences, information about molecular structure or function, and other data generated through the characterization of genetic resources. No single interpretation of these broader boundaries applies across all international agreements.\n\nSequence records are commonly accompanied by metadata: information about the organism, sample, collection location, sequencing method, or associated publication. Metadata are not themselves necessarily sequence information, but they can be essential for interpreting a sequence and establishing its provenance. A sequence with no reliable organism identification or sampling context may have much less scientific value than the same sequence with well-documented metadata.\n\nThe policy meaning of DSI should also be distinguished from all biological information stored digitally. An ecological survey, a photograph of an organism, and a sequence file are not automatically equivalent categories. In the CBD context, human genetic resources fall outside the Convention’s framework."
    },
    {
      "heading": "How sequence information is produced and used",
      "text": "DNA sequencing converts observations of genetic material into machine-readable sequence data. Computational processing can then check quality, combine overlapping reads, identify genes, and compare sequences with existing records. RNA sequencing can reveal expressed transcripts, while protein sequences can be inferred from coding sequences or established experimentally.\n\nA simplified sequence-data workflow is:\n\n- A biological sample is collected or obtained from a collection.\n- Genetic material is extracted and sequenced.\n- Raw data are processed into sequence records.\n- Sequences and metadata are deposited in a database or retained under specified access conditions.\n- Subsequent users analyze, combine, or apply those records.\n\nThese stages need not occur in the same country or institution. Once deposited, a sequence can be copied and analyzed repeatedly without any further transfer of the original specimen.\n\nSequence comparison supports phylogenetic analysis, the identification of organisms, and investigation of gene function. In metagenomics, sequences from mixed samples reveal organisms and biological functions without requiring every organism to be cultured separately. Environmental DNA studies use genetic traces in water, soil, or other material to investigate the presence and distribution of organisms.\n\nApplications extend to agriculture, industrial biotechnology, conservation, and basic biological research. Sequence data can inform crop improvement, the identification of useful enzymes, and the design of laboratory experiments. Computational analysis can also guide the synthesis of genetic material. Nevertheless, a sequence alone does not fully determine the behavior of an organism or the performance of a biological product: cellular context, regulation, environmental conditions, and experimental validation remain important."
    },
    {
      "heading": "Databases and open research",
      "text": "Public sequence databases allow researchers to compare new observations with existing knowledge. The International Nucleotide Sequence Database Collaboration links major nucleotide archives in Europe, Japan, and the United States, exchanging data to support a widely accessible scientific record.\n\nOpen access has several practical advantages:\n\n- Researchers can reproduce or reassess published analyses.\n- Newly obtained sequences can be identified through comparison.\n- Large datasets can be analyzed across many organisms and regions.\n- Laboratories can use existing information without repeating sample collection and sequencing.\n\nHowever, public availability does not establish that every record has complete provenance or identical legal conditions. Database access, permissions associated with the original sample, publication obligations, and the legal treatment of downstream uses are separate questions.\n\nAccess is also not equivalent to an equal ability to benefit. Institutions differ in computing capacity, reliable connectivity, trained personnel, laboratory facilities, and funding. Consequently, debates about DSI include both financial benefit-sharing and the distribution of research capabilities."
    },
    {
      "heading": "Relationship to genetic resources and benefit-sharing",
      "text": "The CBD, adopted in 1992, has three objectives: conserving biological diversity, promoting its sustainable use, and ensuring the fair and equitable sharing of benefits arising from the utilization of genetic resources. It recognizes states’ sovereign rights over their natural resources and establishes a framework in which access to genetic resources is subject to national legislation.\n\nThe Nagoya Protocol, adopted in 2010 and in force since 2014, develops rules on access and benefit-sharing (ABS). Depending on the applicable rules, access to a genetic resource may require prior informed consent and mutually agreed terms. Benefits can include payments, research collaboration, technology transfer, training, or access to research results.\n\nDSI complicates arrangements organized around the transfer of physical material. A researcher may download a sequence from a public database, combine it with thousands of others, and develop an application without receiving a specimen from the country where the original organism was collected.\n\nSeveral difficulties follow:\n\n- Provenance: records may lack sufficient information about where or under what conditions material was obtained.\n- Shared occurrence: the same or very similar sequence may occur in organisms found in multiple countries.\n- Multiple inputs: an analysis or product may depend on many datasets rather than one identifiable resource.\n- Indirect use: sequence information may contribute through comparison, model training, or intermediate research rather than direct incorporation into a product.\n- Administrative scale: negotiating separate terms for every sequence could impose substantial burdens on databases and researchers.\n\nThe legal treatment of DSI cannot therefore be inferred solely from the fact that a sequence is downloadable. Relevant national legislation, contractual arrangements, and international frameworks may differ."
    },
    {
      "heading": "Development of the multilateral approach",
      "text": "DSI became an explicit subject of CBD negotiations during the 2010s. A central question was how to share benefits from its use while preserving the scientific value of accessible sequence databases.\n\nAt its fifteenth meeting in 2022, the CBD Conference of the Parties agreed to establish a multilateral mechanism for sharing benefits from the use of DSI on genetic resources, including a global fund. The same meeting adopted the Kunming–Montreal Global Biodiversity Framework, whose Target 13 addresses benefit-sharing from genetic resources, DSI, and associated traditional knowledge.\n\nIn 2024, at the sixteenth meeting of the Conference of the Parties in Cali, Colombia, parties adopted arrangements to operationalize this mechanism. The resulting Cali Fund was launched in February 2025.\n\nThe mechanism is intended to collect contributions from commercial users benefiting from DSI and distribute resources through a collective system, rather than requiring each use to be traced to a particular sequence provider. The adopted arrangements identify sectors that may benefit from DSI and indicative contribution levels for qualifying entities. They also provide for support to Indigenous peoples and local communities.\n\nThese arrangements should not be equated with a uniform, directly enforceable global tax on sequence downloads. Implementation involves national measures, institutional arrangements, and the participation of commercial users. The multilateral mechanism also does not resolve every question concerning national ABS laws or other specialized international instruments."
    },
    {
      "heading": "Principal policy questions",
      "text": "Open access and equitable returns\n\nA major policy objective is to preserve broad access while addressing unequal distributions of commercial and scientific benefits. Restrictions on access could impede comparative research, biodiversity monitoring, and reproducibility. Conversely, unrestricted availability alone does not ensure that countries and communities associated with genetic resources receive benefits from subsequent applications.\n\nMultilateral financing seeks to reduce the need for transaction-by-transaction permissions, but its effectiveness depends on participation, funding, allocation rules, and implementation.\n\nAttribution and measurement\n\nThe contribution of DSI to a commercial outcome is often difficult to isolate. A sequence may be essential to an early discovery but only one input among many in later development. Revenue, profit, database activity, and individual sequence use measure different things; none automatically provides a complete account of the value derived from genetic information.\n\nCommunity interests and data governance\n\nGenetic resources may be connected to Indigenous peoples’ and local communities’ lands, knowledge, and stewardship. Questions about participation, consent, attribution, and benefit distribution can therefore extend beyond relations between states and companies.\n\nBroad access to scientific data must also be distinguished from unrestricted use of associated sensitive information. Detailed locality data may expose threatened organisms, while some metadata may raise privacy or community-governance concerns. Addressing those issues does not necessarily require closing the underlying sequence record.\n\nBoundaries with other legal regimes\n\nDSI governance intersects with intellectual property, database conditions, research agreements, and specialized systems governing particular genetic resources. Public disclosure of a sequence does not by itself settle whether a downstream invention can receive a patent, nor does a patent determine whether ABS obligations have been met. These are distinct legal questions whose answers depend on the applicable framework."
    }
  ],
  "links": [
    "nucleotide",
    "dna",
    "rna",
    "protein",
    "convention-on-biological-diversity",
    "genome",
    "dna-sequencing",
    "phylogenetics",
    "metagenomics",
    "environmental-dna",
    "biodiversity",
    "nagoya-protocol",
    "kunming-montreal-global-biodiversity-framework",
    "intellectual-property"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}